Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis

Xinyang Li1, Xianrui Zhong2, Yongbo Wang3, Xiantao Zeng3, Ting Luo1, Qing Liu4*

1 School of Stomatology, Wuhan University, Wuhan, Hubei, China, 2 Department of Computer Science, University of Illinois at Urbana-Champaign, Champaign, Illinois, United States of America, 3 Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China, 4 Department of Epidemiology and Health Statistics, School of Health Sciences, Wuhan University, Wuhan, Hubei, China

* liuqing@whu.edu.cn

Abstract

Objective
We aimed to systematically identify the possible risk factors responsible for severe cases.

Methods
We searched PubMed, Embase, Web of science and Cochrane Library for epidemiological studies of confirmed COVID-19, which include information about clinical characteristics and severity of patients’ disease. We analyzed the potential associations between clinical characteristics and severe cases.

Results
We identified a total of 41 eligible studies including 21060 patients with COVID-19. Severe cases were potentially associated with advanced age (Standard Mean Difference (SMD) = 1.73, 95% CI: 1.34–2.12), male gender (Odds Ratio (OR) = 1.51, 95% CI: 1.33–1.71), obesity (OR = 1.89, 95% CI: 1.44–2.46), history of smoking (OR = 1.40, 95% CI: 1.06–1.85), hypertension (OR = 2.42, 95% CI: 2.03–2.88), diabetes (OR = 2.40, 95% CI: 1.98–2.91), chronic kidney disease (CKD) (OR = 2.97, 95% CI: 1.63–5.41), cerebrovascular disease (OR = 2.47, 95% CI: 1.54–3.97), chronic obstructive pulmonary disease (COPD) (OR = 2.88, 95% CI: 1.89–4.38), malignancy (OR = 2.60, 95% CI: 2.00–3.40), and chronic liver disease (OR = 1.51, 95% CI: 1.06–2.17). Acute respiratory distress syndrome (ARDS) (OR = 39.59, 95% CI: 19.99–78.41), shock (OR = 21.50, 95% CI: 10.49–44.06) and acute kidney injury (AKI) (OR = 8.84, 95% CI: 4.34–18.00) were most likely to prevent recovery. In summary, patients with severe conditions had a higher rate of comorbidities and complications than patients with non-severe conditions.

Conclusion
Patients who were male, with advanced age, obesity, a history of smoking, hypertension, diabetes, malignancy, coronary heart disease, hypertension, chronic liver disease, COPD,
or CKD are more likely to develop severe COVID-19 symptoms. ARDS, shock and AKI were thought to be the main hinderances to recovery.

1. Introduction

Coronavirus Disease 2019 (COVID-19), which was first identified in Wuhan, Hubei Province, China in December 2019, has already swept across the world. The World Health Organization (WHO) has officially declared the outbreak as a pandemic and a public health emergency [1]. As of 9th March 2021, according to WHO, the number of confirmed cases around the world has surged dramatically to 116,166,652 with 2,582,528 deaths, which suggests the general mortality rate is approximately 2.22% [2]. The severity of symptoms among patients infected with COVID-19 varies considerably from being asymptomatic to being a critical illness with lethal complications [3, 4].

Some researchers have suggested that there are several factors possibly responsible for the severity of COVID-19, such as hypertension, diabetes and smoking [5–7]. Therefore, we performed this systematic review and meta-analysis to explore the potential risk posed by critical medical states in COVID-19 patients. Specifically, in this study we have compared the reported clinical characteristics of patients with non-severe and severe COVID-19 in eligible published literature.

2. Method

2.1 Search strategy

The literature search was performed using international databases PubMed, Embase, Web of science and Cochrane Library using the search terms: (“COVID-19” OR “SARS-Cov-2”) AND (“characteristics” OR “clinical”): The specific search strategy is listed in S1 Table. Included studies were published between December 2019 and February 2021. The meta-analysis was conducted in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [8].

2.2 Study selection

To minimize bias, two authors (LXY and ZXR) independently screened titles and abstracts and extracted potentially eligible articles. The full texts of selected articles were then carefully assessed according to the inclusion and exclusion criteria. Disagreements were resolved by discussion, with the third researcher (LQ) to reach a consensus.

2.3 Inclusion and exclusion criteria

Inclusion criteria:(1) case-control studies or cohort studies; (2) articles reporting the clinical characteristics and the severity of disease in patients diagnosed with COVID-19; (3) articles reporting the severity of COVID-19 and details of related factors; (4) articles reporting the specific grading standards of the severity of COVID-19.

The definition of severe disease was based on clinical symptoms, i.e., patients having severe dyspnea, extremely low oxygen saturation, respiratory distress or requiring mechanical ventilation, ICU admission or death.

The exclusion criteria: (1) review articles, letters, comments or opinions; (2) samples of less than 50; (3) incomplete information or full texts unavailable.
2.4 Quality assessment

All included studies were retrospective cohort studies so, the Newcastle-Ottawa Scale (NOS) was used to evaluate quality [9]. The major components include: representativeness of the exposed cohort, selection of the non-exposed cohort, ascertainment of exposure, demonstration that outcome of interest was not present at start of study, comparability, assessment of outcome, follow-up time and adequacy of follow up of cohorts. The quality rating is from 0 to 10 stars and the score \( \geq 7 \) stars indicates high-quality articles.

2.5 Data extraction

Two independent authors (LXY and ZXR) performed the data extraction by using standardized forms, which included date of publication, authors, region, number of included patients, sex, body mass index (BMI), smoking habits, comorbidities, complications, and severe or non-severe COVID-19.

2.6 Statistical analysis

We calculated odds ratios (ORs) in the dichotomous variables and standard mean difference (SMD) in the continuous variables with the 95% confidence intervals (CIs) and assessed publication bias using Stata 12.0. Heterogeneity was measured by \( I^2 \) statistic. We used a Mantel-Haenszel random effects model to calculate effect sizes. In order to discover the potential sources of heterogeneity, we performed subgroup analyses and meta-regression analysis according to study location (Hubei province and outside Hubei province) and the median ages of patients. The stability of results was assessed by conducting a sensitivity analysis which omitted each study in turn. Funnel plots were used to assess for publication bias and asymmetry was taken to indicate bias. In this study, \( P \) values < 0.05 were regarded as indicating statistical significance for the summary OR and SMD. In order to quantify the effects of risk factors on COVID-19 patients, we calculated population attributable fraction (PAF) by using the attributable fraction formula:

\[
PAF = P_c \times \frac{RR - 1}{RR}
\]

where \( P_c \) is the prevalence of the risk factors in the population [10]. In this analysis, the ORs were used as approximations of RRs.

3 Results

3.1 Study selection and characteristics

The complete literature-search process is displayed in Fig 1. The search strategy initially retrieved 10314 articles, 10273 of which were excluded by assessing the eligibility criteria. Of these studies, 764 papers were duplicates, 9442 were perceived as unrelated research and 67 articles were in line with exclusion criteria. Finally, 41 articles [11–51] published between February 7th, 2020 and March 13th, 2021 were included, all of which were retrospective cohort studies. In total, 21060 patients were included in the meta-analysis. The characteristics of all the included studies are shown in Table 1.

3.2 Quality evaluation

The results of the quality evaluation of the included retrospective cohort studies are displayed in Table 2. Because of the urgent need for published results on COVID-19 during the
outbreak, some studies [11–15, 18, 19, 22, 23, 27, 29, 30, 34, 40, 43, 48, 49, 51] had limited follow up times.

3.3 Summary of the meta-analysis for primary outcomes

We identified 15 risk factors in three categories (demographic characteristics, comorbidities, complications) that have impact on the severity of confirmed cases. All statistically significant factors in our analysis are summarized in Table 3.

3.4 Demographic characteristics

The demographic characteristics including sex, age, smoking history and BMI were pooled for meta-analysis and the results are displayed in Fig 2. There were 39 studies reporting on sex difference, and the pooled result showed that males were more likely to have severe disease than females (OR = 1.51, 95% CI:1.33–1.71; $I^2 = 50.8\%$) [11–18, 20, 22–51]. Advanced age (SMD = 1.73, 95% CI: 1.34–2.12; $I^2 = 98.6\%$) [11–17, 22–24, 26, 29, 31–35, 38, 39, 41–51] was also considered to be a risk factor for severe COVID-19. In all selected studies, the mean age of patients with severe conditions was older than those with non-severe conditions except for the studies from Wang 2020c [35] and Kim 2020 [46]. Patients with a history of smoking were also found to be positively associated with severe disease (OR = 1.40, 95% CI:1.06–1.85; $I^2 = 30.6\%$).
Table 1. Characteristics of the included studies.

| Author      | Publication Date | Study Location | Samples(M/F) | Severe | Non-severe | Overall age (Median age/ Mean age, range/SD) | Adjustments |
|-------------|------------------|----------------|--------------|--------|------------|------------------------------------------|-------------|
| Wang et al. 2020a [11] | Feb 7, 2020       | Wuhan, China   | 138(75/63)   | 36     | 102        | 56(42–68)                                |             |
| Zhang et al. 2020a [12] | Feb 19, 2020      | Wuhan, China   | 140(71/69)   | 58     | 82         | 57(25–87)                                |             |
| Guan et al. 2020 [13] | Feb 28, 2020      | China          | 1099(640/459)| 173    | 926        | 47(35–58)                                |             |
| Wan et al. 2020 [14]  | Mar 21, 2020      | Chongqing, China| 135(73/62)   | 40     | 95         | 47(36–55)                                |             |
| Hong et al. 2020 [15] | Apr 24, 2020      | Daegu, Korea   | 98(38/60)    | 13     | 85         | 55.4(SD = 17.1)                         |             |
| Zhang et al. 2020b [16] | Apr 27, 2020      | Guangdong, China| 1350(664/686)| 43     | 102        | 45.3(SD = 17.9)                         |             |
| Chen et al. 2020 [17]  | Apr 29, 2020      | Hubei, China   | 73           | 30     | 43         | 46’                                      |             |
| Zhao et al. 2020 [18]  | Apr 30, 2020      | Hubei, China   | 73           | 30     | 43         | 43(21–76)                               |             |
| Hu et al. 2020 [20]    | May 3, 2020       | Wuhan, China   | 323(166/157) | 151    | 172        | 61(23–91)                                |             |
| Cai et al. 2020a [21]  | May 14, 2020      | Shenzhen, China| 383(183/200) | 91     | 292        | NA                                      |             |
| Wang et al. 2020b [22] | May 19, 2020      | Guangzhou, China| 275(134/141)| 45     | 230        | 49(34–62)                               |             |
| Buckner et al. 2020 [23] | May 22, 2020     | Seattle, USA   | 99(53/46)    | 51     | 54         | 69(23–97)                               |             |
| Yang et al. 2020 [24]  | May 25, 2020      | Wuhan, China   | 136(66/70)   | 33     | 103        | 56(44–64)                                |             |
| Feng et al. 2020 [25]  | Jun 1, 2020       | China          | 476(271/205) | 124    | 352        | 53(40–64)                                |             |
| Suleyman et al. 2020 [26] | Jun 16, 2020    | Detroit, USA   | 463(165/298) | 141    | 214        | 57.5(16.8)                              |             |
| Cao et al. 2020 [27]   | Jun 17, 2020      | Beijing, China | 80(38/42)    | 27     | 53         | 53(SD = 20)                             |             |
| Shahriarirad et al. 2020 [28] | Jun 18, 2020 | Iran           | 113(71/42)   | 11     | 102        | 53.75(20–99)                            |             |
| Nie et al. 2020 [29]   | Jun 26, 2020      | Henan, China   | 671(367/304) | 72     | 583        | 44(31–53)                               |             |
| Zhang et al. 2020c [30] | Jul 8, 2020       | Zhejiang, China| 771(394/337) | 61     | 710        | NA                                      |             |
| Cai et al. 2020b [31]  | Jul 11, 2020      | Shenzhen, China| 298(145/153) | 240    | 58         | 47(33–61)                               |             |
| Gregoriano et al. 2020 [32] | Jul 15, 2020  | Switzerland    | 99(62/37)    | 35     | 64         | 67(56–76)                               |             |
| Ghweil et al. 2020 [33] | Jul 17, 2020      | Egypt          | 66(48/18)    | 30     | 36         | 55.5(SD = 10.1)                         |             |
| Yu et al. 2020 [34]    | Jul 17, 2020      | Wuhan, China   | 1663(838/825)| 864    | 799        | 64(52–71)                               |             |
| Wang et al. 2020c [35] | Jul 18, 2020      | Wuhan, China   | 483(218/265) | 421    | 62         | 48.4(SD = 12.4)                         |             |
| Lee et al. 2020 [36]   | Jul 21, 2020      | Daegu, Korea   | 694(212/482) | 137    | 557        | 52.1(SD = 18.29)                        |             |
| Xu et al. 2020 [37]    | Jul 25, 2020      | Wuhan, China   | 88(36/52)    | 41     | 47         | 57.11(SD = 15.39)                       |             |

(Continued)
In studies which reported BMI, we observed higher rates of obesity (BMI ≥ 30kg/m²) in patients with severe disease (OR = 1.89, 95% CI: 1.44–2.46; I² = 0.0%) [20, 21, 23, 26, 30, 35].

3.5 Comorbidities

Fig 3 shows the potential association between seven comorbidities and the risk of severe COVID-19 using ORs. Compared with patients having non-severe disease, there was a higher potential for patients having severe conditions to have one or more comorbidities. Results show that CKD had the highest OR value at 2.97 (95% CI: 1.63–5.41; I² = 68.4%) [11–13, 17, 20, 22–26, 28, 30–32, 34–36, 41–43, 45, 47, 51], followed by COPD with the OR of 2.88 (95% CI: 2.33–3.58; I² = 52.6%) [11–15, 17, 20, 23, 25–30, 32, 34, 36–38, 41, 43, 45, 48, 49, 51]. Other significant outcomes included coronary heart disease (OR: 2.87, 95% CI: 2.22–3.71; I² = 59.9%) [11–15, 17, 20, 22–38, 41–45, 47, 49–51], malignancy (OR = 2.60, 95% CI: 2.00–3.40; I² = 11.9%) [11, 13, 15, 17, 20, 22–26, 28, 30–32, 34–38, 41, 43], chronic obstructive pulmonary disease (COPD) (OR: 2.87, 95% CI: 2.22–3.71; I² = 59.9%) [11–15, 17, 20, 22–38, 41–45, 47, 49–51], hypertension (OR = 2.42, 95% CI: 2.03–2.88; I² = 67.9%) [11–18, 20, 22–51], diabetes

* Zhao et al. 2020 [18] only reported median age without age range

https://doi.org/10.1371/journal.pone.0250602.t001

PLOS ONE | https://doi.org/10.1371/journal.pone.0250602 May 3, 2021 6 / 21

[12, 13, 17, 19, 20, 22, 23, 25–27, 29, 30, 33, 35, 38, 40, 41, 43, 48, 50]. In studies which reported BMI, we observed higher rates of obesity (BMI ≥ 30kg/m²) in patients with severe disease (OR = 1.89, 95% CI: 1.44–2.46; I² = 0.0%) [20, 21, 23, 26, 30, 35].

3.5 Comorbidities

Fig 3 shows the potential association between seven comorbidities and the risk of severe COVID-19 using ORs. Compared with patients having non-severe disease, there was a higher potential for patients having severe conditions to have one or more comorbidities. Results show that CKD had the highest OR value at 2.97 (95% CI: 1.63–5.41; I² = 68.4%) [11–13, 17, 20, 22, 25, 26, 28, 30, 32, 34, 36, 41–43, 45, 47, 51], followed by COPD with the OR of 2.88 (95% CI: 1.89–4.38; I² = 52.6%) [11–15, 17, 20, 23, 25–30, 32, 34, 36–38, 41, 43, 45, 48, 49, 51]. Other significant outcomes included coronary heart disease (OR: 2.87, 95% CI: 2.22–3.71; I² = 59.9%) [11–15, 17, 20, 22–38, 41–45, 47, 49–51], malignancy (OR = 2.60, 95% CI: 2.00–3.40; I² = 11.9%) [11, 13, 15, 17, 20, 22–26, 28, 30–32, 34–38, 41, 43], chronic obstructive pulmonary disease (COPD) (OR: 2.87, 95% CI: 2.22–3.71; I² = 59.9%) [11–15, 17, 20, 22–38, 41–45, 47, 49–51], hypertension (OR = 2.42, 95% CI: 2.03–2.88; I² = 67.9%) [11–18, 20, 22–51], diabetes
| Author                | Representativeness of the exposed cohort | Selection of the non-exposed cohort | Ascertainment of exposure | Demonstration that outcome of interest was not present at start of study | Comparability | Assessment of outcome | Follow-up time | Adequacy of follow-up of cohorts | Total |
|-----------------------|----------------------------------------|-------------------------------------|---------------------------|----------------------------------------------------------------------|--------------|----------------------|--------------|-------------------------------|-------|
| Wang et al. 2020a [11]| ☆                                      | ☆                                   | ☆                         | ☆                                                                     | ☆            | ☆                   | ☆            | ☆                             | 7     |
| Zhang et al. 2020a [12]| ☆                                      | ☆                                   | ☆                         | ☆                                                                     | ☆            | ☆                   | ☆            | ☆                             | 8     |
| Guan et al. 2020 [13] | ☆                                      | ☆                                   | ☆                         | ☆                                                                     | ☆            | ☆                   | ☆            | 6                             | 6     |
| Wan et al. 2020 [14]  | ☆                                      | ☆                                   | ☆                         | ☆                                                                     | ☆            | ☆                   | ☆            | 7                             | 7     |
| Hong et al. 2020 [15] | ☆                                      | ☆                                   | ☆                         | ☆                                                                     | ☆            | ☆                   | ☆            | 7                             | 7     |
| Zhang et al. 2020b [16]| ☆                                      | ☆                                   | ☆                         | ☆                                                                     | ☆            | ☆                   | ☆            | 8                             | 8     |
| Chen et al. 2020 [17] | ☆                                      | ☆                                   | ☆                         | ☆                                                                     | ☆            | ☆                   | ☆            | 7                             | 7     |
| Zhao et al. 2020 [18] | ☆                                      | ☆                                   | ☆                         | ☆                                                                     | ☆            | ☆                   | ☆            | 6                             | 6     |
| Zheng et al. 2020 [19]| ☆                                      | ☆                                   | ☆                         | ☆                                                                     | ☆            | ☆                   | ☆            | 9                             | 9     |
| Hu et al. 2020 [20]   | ☆                                      | ☆                                   | ☆                         | ☆                                                                     | ☆            | ☆                   | ☆            | 9                             | 9     |
| Cai et al. 2020a [21] | ☆                                      | ☆                                   | ☆                         | ☆                                                                     | ☆            | ☆                   | ☆            | 7                             | 7     |
| Wang et al. 2020b [22]| ☆                                      | ☆                                   | ☆                         | ☆                                                                     | ☆            | ☆                   | ☆            | 7                             | 7     |
| Buckner et al. 2020 [23]|☆                                        |☆                                   |☆                         |☆                                                                     |☆            |☆                   |☆            |7                             |7     |
| Yang et al. 2020 [24]| ☆                                      |☆                                   |☆                         |☆                                                                     |☆            |☆                   |☆            |8                             |8     |
| Feng et al. 2020 [25]| ☆                                      |☆                                   |☆                         |☆                                                                     |☆            |☆                   |☆            |9                             |9     |
| Suleyman et al. 2020 [26]|☆                                        |☆                                   |☆                         |☆                                                                     |☆            |☆                   |☆            |9                             |9     |
| Cao et al. 2020 [27]  |☆                                      |☆                                   |☆                         |☆                                                                     |☆            |☆                   |☆            |7                             |7     |
| Shahriarirad et al. 2020 [28]|☆                                        |☆                                   |☆                         |☆                                                                     |☆            |☆                   |☆            |8                             |8     |
| Nie et al. 2020 [29]  |☆                                      |☆                                   |☆                         |☆                                                                     |☆            |☆                   |☆            |8                             |8     |
| Zhang et al. 2020c [30]|☆                                        |☆                                   |☆                         |☆                                                                     |☆            |☆                   |☆            |8                             |8     |
| Cai et al. 2020b [31]|☆                                      |☆                                   |☆                         |☆                                                                     |☆            |☆                   |☆            |9                             |9     |
| Gregoriano et al. 2020 [32]|☆                                        |☆                                   |☆                         |☆                                                                     |☆            |☆                   |☆            |8                             |8     |
| Ghweil et al. 2020 [33]|☆                                      |☆                                   |☆                         |☆                                                                     |☆            |☆                   |☆            |8                             |8     |
| Yu et al. 2020 [34]   |☆                                      |☆                                   |☆                         |☆                                                                     |☆            |☆                   |☆            |7                             |7     |
| Wang et al. 2020c [35]|☆                                      |☆                                   |☆                         |☆                                                                     |☆            |☆                   |☆            |7                             |7     |
(OR = 2.40, 95% CI: 1.98–2.91; \(I^2 = 55.6\%\)) [11–20, 22–45, 47–51] and chronic liver disease (OR = 1.51, 95% CI: 1.06–2.17; \(I^2 = 0.0\%\)) [11–15, 17, 20, 22–26, 28, 30–32, 34–38, 41, 43–44, 47, 50]. While the analyses of asthma (OR = 1.93, 95% CI: 0.81–4.61; \(I^2 = 79.4\%\)) [26, 28, 35, 38, 45] showed no significant differences between patients with severe and non-severe disease.

### 3.6 Complications

The results shown in Fig 4 indicate that ARDS (OR = 39.59, 95% CI: 19.99–78.41; \(I^2 = 48.7\%\)) [11, 13–15, 17, 20, 22–26, 28, 30–32, 34–38, 41, 43–44, 47, 50], shock (OR = 21.50, 95% CI: 10.49–44.06; \(I^2 = 27.4\%\)) [11, 13, 15, 17, 20, 22, 24, 43, 44, 51] and AKI (OR = 8.84, 95% CI: 4.34–18.00; \(I^2 = 40.7\%\)) [11, 13–15, 18, 20, 24, 44, 51] which are potential life-threatening conditions, were clearly responsible for the ICU admissions. Additionally, some other complications like DIC (OR = 29.75, 95% CI: 3.41–259.68; \(I^2 = 0.0\%\)) [13, 22], secondary infection (OR = 10.03, 95% CI: 1.99–50.55; \(I^2 = 39.0\%\)) [14, 25], arrhythmia (OR = 9.80, 95% CI: 3.91–24.60; \(I^2 = 0.0\%\)) [11, 12] and cardiac trauma (OR = 7.38, 95% CI: 2.28–23.82; \(I^2 = 75.0\%\)) [11, 14, 15, 18, 24, 51] also potentially increase the severity of COVID-19. Though we lacked sufficient evidence to support the results.

### Table 2. (Continued)

| Author          | Representativeness of the exposed cohort | Selection of the non-exposed cohort | Ascertainment of exposure | Demonstration that outcome of interest was not present at start of study | Comparability | Assessment of outcome | Follow-up time | Adequacy of follow-up of cohorts | Total |
|-----------------|-----------------------------------------|-------------------------------------|---------------------------|------------------------------------------------------------------------|--------------|----------------------|----------------|----------------------------------|-------|
| Lee et al. 2020 [36] | ☆                                      | ☆                                   | ☆                         | ☆                                                                       | ☆            | ☆                   | ☆              | ☆                                | 8     |
| Xu et al. 2020 [37] | ☆                                      | ☆                                   | ☆                         |                                                                         |              |                     |                |                                   | 7     |
| Wei et al. 2020 [38] | ☆                                      | ☆                                   | ☆                         |                                                                         |              |                     |                |                                   | 9     |
| Liu et al. 2020 [39] | ☆                                      | ☆                                   | ☆                         |                                                                         |              |                     |                |                                   | 9     |
| Wang et al. 2020d [40] | ☆                                      | ☆                                   | ☆                         |                                                                         |              |                     |                |                                   | 7     |
| Ishii et al. 2020 [41] | ☆                                      | ☆                                   | ☆                         |                                                                         |              |                     |                |                                   | 9     |
| Shu et al. 2020 [42] | ☆                                      | ☆                                   | ☆                         |                                                                         |              |                     |                |                                   | 9     |
| Du et al. 2020 [43] | ☆                                      | ☆                                   | ☆                         |                                                                         |              |                     |                |                                   | 7     |
| Xiong et al. 2020 [44] | ☆                                      | ☆                                   | ☆                         |                                                                         |              |                     |                |                                   | 8     |
| Lee et al. 2020b [45] | ☆                                      | ☆                                   | ☆                         |                                                                         |              |                     |                |                                   | 8     |
| Kim et al. 2020 [46] | ☆                                      | ☆                                   | ☆                         |                                                                         |              |                     |                |                                   | 8     |
| Ren et al. 2020 [47] | ☆                                      | ☆                                   | ☆                         |                                                                         |              |                     |                |                                   | 9     |
| Vial et al. 2020 [48] | ☆                                      | ☆                                   | ☆                         |                                                                         |              |                     |                |                                   | 8     |
| Lv et al. 2021 [49] | ☆                                      | ☆                                   | ☆                         |                                                                         |              |                     |                |                                   | 7     |
| Zhang et al. 2021a [50] | ☆                                      | ☆                                   | ☆                         |                                                                         |              |                     |                |                                   | 8     |
| Zhang et al. 2021b [51] | ☆                                      | ☆                                   | ☆                         |                                                                         |              |                     |                |                                   | 7     |

https://doi.org/10.1371/journal.pone.0250602.t002
for these other complications except for shock, ARDS and AKI, the data we already had were of high consistency. However, some complications such as hypohepatia (OR = 1.53, 95% CI: 0.71–3.30; \(I^2 = 0.0\%\)) [18, 24] did not show obvious association with the severity of patients’ conditions.

### 3.7 Population attributable risk

We calculated the population attributable risk (PAR) of the population infected with COVID-19. PAR reflects the proportion of severe COVID-19 that can be attributed to exposure to a risk factor. Table 4 shows that the PARs ranged from 0.9% to 11.3%, with the estimated attributable fraction in COVID-19 patients being 11.3% for hypertension and 7.1% for obesity. It is suggested that up to 11.3% and 7.1% of severe cases could have been avoided if the prevalences of hypertension and obesity were reduced.

### 3.8 Subgroup analysis and meta-regression analysis

We performed subgroup analyses to identify the possible sources of heterogeneity of some outcomes. We tried to analyze several factors such as study location, publication date, sample size and patients’ average age of which study location gave a relatively meaningful result as shown in Table 5. This shows high consistency among the studies conducted in Hubei province but the heterogeneity of the studies outside Hubei province is also significant. Interestingly, the studies conducted in Hubei province show the ORs of ARDS was much lower than other regions. The meta-regression analysis demonstrates that the association between coronary heart disease and increased severity was influenced by age (\(P = 0.013\)), and the discrepancy between patients’ median ages in eligible studies partly contributed to the heterogeneity. (Fig 5)

### 3.9 Sensitivity analysis and publication bias

By excluding every article in turn, we conducted a sensitivity analysis and there was no evident change in either the significant outcomes or in heterogeneity. To assess the risk of publication bias, we drew a funnel plot for each factor. The results, displayed in S1 Fig, show that nearly all
the funnel plots are symmetrical except for cerebrovascular disease, which suggests the risk of publication bias is low in our analysis.

4 Discussion

This study has examined the potential risk factors of severe COVID-19 such as demographic characteristics, comorbidities and complications to assist clinicians with allocation of medical resources. The higher the ORs of the risk factors, the greater the risks they bring. Our analysis has shown that males, obese patients (BMI \( \geq 30 \text{kg/m}^2 \)), patients with advanced age or a smoking history faced a greater risk of having severe COVID-19. This finding has also been supported by some previous studies [52–54]. However, some of the results of one meta-analysis were not consistent with our analysis, since they found gender irrelevant to the severity of COVID-19, which may possibly be due to the relatively small sample size [55]. The comorbidities including hypertension, diabetes, CKD, coronary heart disease, COPD, cerebrovascular disease and chronic liver disease could probably aggravate the illness and this outcome was consistent with other studies. [5, 7, 55–57] Complications including shock, AKI and ARDS
### Risk factors of COVID-19

#### (A) Chronic kidney disease

| Study | OR (95% CI) | Weight |
|-------|-------------|--------|
| Wang et al. 2020 | 2.34 (1.04, 5.20) | 4.59 |
| Zhang et al. 2020 | 1.63 (0.29, 9.03) | 0.17 |
| Gao et al. 2020 | 0.35 (0.07, 1.69) | 0.05 |
| Chen et al. 2020 | 1.19 (0.13, 10.49) | 0.19 |
| Hu et al. 2019 | 0.76 (0.46, 1.29) | 0.7 |
| Wang et al. 2020 | 1.68 (0.95, 2.95) | 0.44 |
| Fang et al. 2020 | 2.45 (0.99, 6.05) | 0.10 |
| Shang et al. 2020 | 0.65 (0.13, 3.23) | 0.32 |
| Zhang et al. 2020 | 3.25 (0.17, 6.22) | 0.21 |
| Ge et al. 2020 | 1.83 (0.32, 9.95) | 0.78 |
| Yu et al. 2020 | 2.00 (0.87, 4.56) | 2.17 |
| Lee et al. 2020 | 16.12 (0.16, 0.23) | 0.05 |
| Jeon et al. 2020 | 7.02 (0.39, 13.16) | 0.09 |
| Shu et al. 2020 | 2.64 (1.21, 5.02) | 0.20 |
| Xu et al. 2020 | 4.91 (0.70, 3.69) | 0.14 |
| Ren et al. 2020 | 4.13 (0.52, 5.69) | 0.68 |
| Overall (random-effects model) | 2.37 (1.03, 5.41) | 1.00 |

**Note:** Weights are from random-effects analysis.

#### (B) Chronic obstructive pulmonary disease

| Study | OR (95% CI) | Weight |
|-------|-------------|--------|
| Wang et al. 2020 | 8.12 (0.07, 92.23) | 2.94 |
| Zhang et al. 2020 | 1.02 (0.05, 20.05) | 0.10 |
| Gao et al. 2020 | 5.48 (0.17, 170.25) | 0.31 |
| Han et al. 2020 | 6.87 (0.05, 78.46) | 0.03 |
| Wang et al. 2020 | 1.68 (0.33, 8.74) | 0.34 |
| Bouchard et al. 2019 | 1.39 (0.36, 5.49) | 0.11 |
| Fenyi et al. 2019 | 5.69 (0.17, 170.25) | 0.31 |
| Kocyak et al. 2019 | 1.38 (0.29, 6.93) | 0.11 |
| Delaporte et al. 2019 | 5.71 (0.26, 125.90) | 0.34 |
| Delaporte et al. 2020 | 0.90 (0.42, 1.88) | 0.04 |
| Delaporte et al. 2021 | 5.26 (0.23, 119.29) | 0.30 |
| Delaporte et al. 2022 | 1.39 (0.36, 5.49) | 0.11 |
| Delaporte et al. 2023 | 5.69 (0.17, 170.25) | 0.31 |
| Delaporte et al. 2024 | 1.38 (0.29, 6.93) | 0.11 |
| Overall (random-effects model) | 5.11 (0.10, 119.29) | 0.30 |

**Note:** Weights are from random-effects analysis.

#### (C) Coronary heart disease

| Study | OR (95% CI) | Weight |
|-------|-------------|--------|
| Wang et al. 2020 | 2.70 (1.55, 4.67) | 2.40 |
| Zhang et al. 2020 | 1.95 (0.43, 9.03) | 0.37 |
| Gao et al. 2020 | 0.51 (0.09, 2.95) | 0.03 |
| Han et al. 2020 | 10.14 (0.16, 64.40) | 0.17 |
| Deng et al. 2020 | 6.31 (0.32, 126.78) | 0.37 |
| Yu et al. 2020 | 4.53 (0.99, 21.54) | 0.20 |
| Zhang et al. 2020 | 3.47 (0.78, 14.77) | 0.11 |
| Rong et al. 2020 | 0.96 (0.18, 5.30) | 0.05 |
| Overall (random-effects model) | 1.66 (0.83, 3.33) | 0.19 |

**Note:** Weights are from random-effects analysis.

#### (D) Malignancy

| Study | OR (95% CI) | Weight |
|-------|-------------|--------|
| Wang et al. 2020 | 2.65 (0.33, 20.05) | 0.10 |
| Zhang et al. 2020 | 1.39 (0.36, 5.49) | 0.11 |
| Gao et al. 2020 | 5.69 (0.17, 170.25) | 0.31 |
| Han et al. 2020 | 1.38 (0.29, 6.93) | 0.11 |
| Overall (random-effects model) | 1.55 (0.36, 6.93) | 0.11 |

**Note:** Weights are from random-effects analysis.

#### (E) Cerebrovascular disease

| Study | OR (95% CI) | Weight |
|-------|-------------|--------|
| Wang et al. 2020 | 2.93 (0.34, 24.00) | 0.21 |
| Gao et al. 2020 | 1.58 (0.42, 5.73) | 0.09 |
| Han et al. 2020 | 1.32 (0.33, 5.49) | 0.09 |
| Overall (random-effects model) | 2.47 (0.56, 10.00) | 0.07 |

**Note:** Weights are from random-effects analysis.

#### (F) Hypertension

| Study | OR (95% CI) | Weight |
|-------|-------------|--------|
| Wang et al. 2020 | 2.31 (0.88, 6.22) | 0.47 |
| Zhang et al. 2020 | 6.35 (0.13, 293.78) | 0.37 |
| Gao et al. 2020 | 1.48 (0.28, 6.93) | 0.09 |
| Han et al. 2020 | 1.21 (0.28, 5.49) | 0.09 |
| Overall (random-effects model) | 1.81 (0.49, 6.85) | 0.10 |

**Note:** Weights are from random-effects analysis.

#### (G) Diabetes

| Study | OR (95% CI) | Weight |
|-------|-------------|--------|
| Wang et al. 2020 | 3.27 (0.69, 14.35) | 0.29 |
| Zhang et al. 2020 | 3.27 (0.69, 14.35) | 0.29 |
| Gao et al. 2020 | 1.98 (0.50, 7.64) | 0.18 |
| Han et al. 2020 | 1.23 (0.27, 5.83) | 0.08 |
| Overall (random-effects model) | 2.31 (0.56, 9.85) | 0.07 |

**Note:** Weights are from random-effects analysis.

#### (H) Chronic liver disease

| Study | OR (95% CI) | Weight |
|-------|-------------|--------|
| Wang et al. 2020 | 0.33 (0.02, 5.71) | 1.46 |
| Zhang et al. 2020 | 1.04 (0.28, 3.80) | 0.30 |
| Gao et al. 2020 | 0.32 (0.09, 1.08) | 0.18 |
| Han et al. 2020 | 2.40 (0.19, 28.32) | 0.16 |
| Overall (random-effects model) | 0.67 (0.01, 37.90) | 0.00 |

**Note:** Weights are from random-effects analysis.
were the main obstacles to recovery. Therefore, more attention should be paid to those obese elderly males with a history of smoking, and the above comorbidities or complications since they are more likely to develop the severe form of the disease. Although four previous studies [52, 53, 55, 57–59] have reported some risk factors for severe COVID-19, our analysis involved and reported on new factors obesity and chronic liver disease. In this study, the quality of evidence was higher since all the included studies were cohort studies rather than case-control studies, and we have included 41 eligible studies that were published from February, 2020 to March, 2021, spanning a period of seven months.

Some studies have suggested that innate immunity and some factors associated with sex chromosomes may lead to the differences in susceptibility and inflammation between females and males. For instance, the X chromosome in the female has encoded some immune regulatory genes which caused lower viral load levels. TLR7, a Toll-like kind of receptor, which is higher in females than males, could enhance immune responses and boost the resistance to COVID-19 [60]. Besides, the circulating concentration of ACE2 (a functional cellular receptor of SARS-CoV-2) is higher in males than females, which could increase the susceptibility to SARS-CoV-2 [61]. Males also smoked at a higher rate than females [62] and that could result in a more vulnerable respiratory system. Therefore, it seems reasonable that women have been found to be more resistant to COVID-19. As for smoking, it suppresses the antiviral mechanisms and alters some cytokine patterns which play a role in the innate mucosal immunity [63]; the viral replication and the severity of COVID-19 would increase to some extent as a result. One study shows that smoking can also enhance the expression of ACE2 [64] and this would raise the susceptibility. With regard to age, it was evident that elderly people had a higher prevalence of comorbidities like diabetes [65] and complications like shock [66], but the OR was still significant when controlling for the above confounding factors. The natural decrease in functional reserve brought about by the physiological aging process could reduce elders’ capability to resist infections like COVID-19. Based on the analysis of an increasing number of studies reporting details of BMI, we considered obesity as a risk factor. Obesity could cause more endothelial dysfunction [67] and weaken the immunocompetent cells especially their cytotoxic cell responses [68]. The high level of ACE2 receptor expression in adipocytes may turn the adipose tissue into a viral carrier which could spread SARS-CoV-2 to other organs.

We also found some comorbidities were potentially high-risk factors for severe disease and this is consistent with other recent studies [53, 55, 57–59]. For example, as a chronic respiratory illness, COPD has already led to airflow blockage and so raises the risk of respiratory complications like ARDS. Psychologically, when patients with COPD get COVID-19, they seem to easily become very afraid and anxious [69]. Negative feelings may drive misbehavior and go against recovery, so psychological support is considered important. Though the degree varied, a large number of COVID-19 patients had hypoxaemia which may cause injury or apoptosis of cardiomyocytes [70]. As a result, patients with coronary heart disease were more likely to suffer from severer conditions like heart failure which can easily lead to death. For patients with hypertension, some kinds of blood pressure medications can enhance the expression of ACE2 and leave patients more susceptible to COVID-19 symptoms [71, 72]. However some other studies have shown that ACE2 plays an anti-inflammatory role in RAS and protect patients from ARDS [73, 74]. Therefore, the incidence of COVID-19 was lower but the severity was
### (A) Acute respiratory distress syndrome

| Study                  | %   | OR (95% CI) | Weight |
|------------------------|-----|-------------|--------|
| Wang et al. 2020a      |     | 30.49 (9.94, 93.54) | 14.92  |
| Guan et al. 2020       |     | 16.88 (8.01, 35.61)  | 19.21  |
| Wan et al. 2020        |     | 94.00 (11.91, 741.62) | 7.61  |
| Hong et al. 2020       |     | 395.18 (20.64, 7654.59) | 4.41  |
| Chen et al. 2020       |     | 7.24 (0.29, 181.16)   | 3.81  |
| Hu et al. 2020         |     | 14.76 (1.90, 114.93)  | 7.66  |
| Wang et al. 2020b      |     | 404.55 (23.76, 6887.03) | 4.71  |
| Yang et al. 2020       |     | 20.83 (6.74, 64.37)   | 14.84 |
| Suleyman et al. 2020   |     | 83.12 (35.83, 192.82) | 18.09 |
| Xiong et al. 2020      |     | 71.03 (4.17, 1210.44) | 4.71  |
| Overall (I-squared = 48.7%, p = 0.041) |     | 39.59 (19.99, 78.41)  | 100.00|

**NOTE:** Weights are from random effects analysis

### (B) Shock

| Study                  | %   | OR (95% CI) | Weight |
|------------------------|-----|-------------|--------|
| Wang et al. 2020a      |     | 44.44 (5.48, 360.52) | 8.98  |
| Guan et al. 2020       |     | 62.60 (8.03, 488.22)  | 9.24  |
| Wan et al. 2020        |     | 7.25 (0.29, 181.90)   | 4.39  |
| Hong et al. 2020       |     | 361.00 (18.02, 7233.81) | 4.99  |
| Chen et al. 2020       |     | 5.73 (3.0, 14.76)     | 20.16 |
| Hu et al. 2020         |     | 14.63 (5.09, 42.06)   | 20.86 |
| Wang et al. 2020b      |     | 15.54 (0.62, 367.62)  | 4.40  |
| Yang et al. 2020       |     | 48.93 (2.67, 895.47)  | 5.25  |
| Du et al. 2020         |     | 35.79 (1.80, 713.39)  | 5.00  |
| Xiong et al. 2020      |     | 51.30 (3.30, 880.93)  | 5.46  |
| Zhang et al. 2021b     |     | 34.71 (1.92, 628.72)  | 5.29  |
| Overall (I-squared = 27.4%, p = 0.163) |     | 21.50 (10.49, 44.08) | 100.00|

**NOTE:** Weights are from random effects analysis

### (C) Acute kidney injury

| Study                  | %   | OR (95% CI) | Weight |
|------------------------|-----|-------------|--------|
| Wang et al. 2020a      |     | 4.55 (0.73, 28.39) | 9.92  |
| Guan et al. 2020       |     | 27.44 (3.19, 236.36) | 7.92  |
| Wan et al. 2020        |     | 0.68 (0.06, 5.39)   | 7.56  |
| Hong et al. 2020       |     | 134.40 (13.94, 1295.98) | 7.35  |
| Zhao et al. 2020       |     | 28.52 (1.41, 497.65) | 4.69  |
| Hu et al. 2020         |     | 9.38 (2.11, 41.70)   | 12.74 |
| Yang et al. 2020       |     | 10.20 (1.02, 101.68) | 7.19  |
| Suleyman et al. 2020   |     | 5.72 (3.59, 9.10)    | 25.84 |
| Xiong et al. 2020      |     | 8.20 (0.41, 162.41)  | 4.74  |
| Zhang et al. 2021b     |     | 11.07 (2.26, 54.19)  | 11.86 |
| Overall (I-squared = 40.7%, p = 0.086) |     | 8.84 (4.34, 18.00)  | 100.00|

**NOTE:** Weights are from random effects analysis
higher in patients with hypertension. Additionally, prolonged hypertension damages the vascular structure leaving the patients susceptible to serious infections. In terms of diabetes, this could compromise and weaken patients’ immune system thus worsening their conditions [75]. The dysfunctional pro-inflammatory cytokine responses due to diabetes could also increase the severity of COVID-19 [7]. Whether malignancy does affect the state of illness or lead to a poor prognosis is still controversial. Though our analysis showed there was a potential relationship between malignancy and severe condition, some articles had conflicting outcomes, and a few articles have even suggested that some patients with cancer may have better clinical outcomes since the possible emergence of cytokine storm was dampened because of their compromised immune systems [76, 77]. In addition to the above results, we have also found chronic renal disease (OR = 2.97, 95% CI: 1.63–5.41) was a potential risk factor for severe COVID-19, although a previous analysis had showed that it was not significantly associated with severe conditions [52]. It is likely that patients with CKD suffer from dysregulation of the immune system [78], which possibly contributed to the increase in severity. A study with similar results to ours has also reported a potential link between chronic liver disease and severe COVID-19 [79]. The hepatic insufficiency of COVID-19 patients could be worsened by potentially hepatotoxic drugs such as remdesivir, lopinavir and ritonavir used to treat the disease, causing more severe conditions [80]. More analyses need to be done in order to provide sufficient information and draw accurate conclusions about the controversial results above.

According to our analysis, ARDS, shock and AKI were the three major complications playing a role in severe conditions. Due to impaired gas exchange and serious inflammation in the alveolar space, patients with ARDS had significant need of ventilation [81]. Some studies [82, 83] suggested tissue plasminogen activator (tPA) may be useful in saving such patients’ lives in the face of lack of mechanic ventilation in some areas. AKI is prevalent among severe patients and can be fatal especially when patients required renal replacement therapy [84]. Similarly, shocked patients can die without timely treatment resulting from the lack of effective circulating blood volume. Therefore, it is essential to prevent the occurrence of the above complications and give prompt first aid treatment when such complications occur.

Table 4. Population attributable risks of risk factors.

| Risk factor                                | Prevalence | OR   | PAR  |
|--------------------------------------------|------------|------|------|
| Smoking history                            | 0.1351     | 1.40 | 3.9% |
| Obesity                                    | 0.1517     | 1.89 | 7.1% |
| Hypertension                               | 0.1926     | 2.42 | 11.3%|
| Diabetes                                   | 0.1121     | 2.40 | 6.5% |
| Coronary heart disease                     | 0.0682     | 2.87 | 4.4% |
| Cerebrovascular disease                    | 0.0299     | 2.47 | 1.8% |
| Chronic obstructive pulmonary disease      | 0.0227     | 2.88 | 1.5% |
| Chronic liver disease                      | 0.0278     | 1.51 | 0.9% |
| Chronic kidney disease                     | 0.0155     | 2.97 | 1.0% |
| Malignancy                                 | 0.0256     | 2.60 | 1.6% |
| Shock                                      | 0.0579     | 21.50| 5.5% |
| Acute respiratory distress syndrome        | 0.1033     | 39.59| 10.7%|
| Acute kidney injury                        | 0.0838     | 8.84 | 7.4% |

https://doi.org/10.1371/journal.pone.0250602.t004
We believe the PAFs we calculated are meaningful for public health, because the risk of severe cases is likely to decrease in the wake of reduction in the prevalence of certain conditions. In our analysis, the top risk factor was hypertension with the score of 11.3%, indicating that though the OR of hypertension was not relatively high among all the factors, it did play a more important role than we had thought. The PAFs of ARDS (10.7%) and AKI (7.4%) were also high which showed that they possibly make a considerable contribution to the severity of COVID-19, but there are no specific clinical guidelines to prevent them. Therefore, more attention should be given to some other factors like obesity (7.1%) and diabetes (6.5%) since they can to some extent be prevented through practical guidelines [85] and public health campaigns. The other factors ranged from 0.9% to 5.5% and half of them were around 1.0%, suggesting that they exert less effects on the severity of COVID-19.

We should acknowledge that there are some limitations which may affect the accuracy of the outcomes and should be considered. First, some studies did not explicitly show their criteria for severe patients and non-severe patients, meaning the actual severity of patients with these two outcomes may not be consistent with those studies. Second, detecting significant heterogeneity in some analyses, we chose to use a random effects model to process data but did not identify the clear sources of heterogeneity through subgroup analyses. Third, the

|                  | Hubei Province         | Outside Hubei Province |
|------------------|------------------------|------------------------|
|                  | N | OR (95%CI) | I² | P   | N | OR (95%CI) | I² | P   |
| COPD             | 8 | 2.78(1.53,5.06) | 25.7% | 0.22 | 17 | 2.67(1.53,4.68) | 58.9% | 0.001 |
| CKD              | 6 | 3.82(1.44,8.11) | 13.5% | 0.33 | 10 | 3.64(1.55,8.58) | 69.1% | 0.001 |
| ARDS             | 5 | 25.25(12.32,51.74) | 0.0% | 0.80 | 6 | 61.22(19.03,196.94) | 67.8% | 0.008 |
| AKI              | 5 | 8.65(3.42,21.85) | 0.0% | 0.90 | 5 | 9.77(2.65,36.01) | 71.1% | 0.08 |

We should acknowledge that there are some limitations which may affect the accuracy of the outcomes and should be considered. First, some studies did not explicitly show their criteria for severe patients and non-severe patients, meaning the actual severity of patients with these two outcomes may not be consistent with those studies. Second, detecting significant heterogeneity in some analyses, we chose to use a random effects model to process data but did not identify the clear sources of heterogeneity through subgroup analyses. Third, the

![Fig 5. Meta-regression by median age of patients.](https://doi.org/10.1371/journal.pone.0250602.g005)
majority of the patients came from China, so they may not be representative of all patients across the world and so results should be carefully evaluated and accepted cautiously. The conclusion can be updated when more studies from outside China are published. Forth, we have tried to include studies from different cites but some articles may still include duplicated cases since they seldom mentioned the detailed composition of patient groups.

5 Conclusion
In summary, patients with COVID-19 who have the following characteristics: male gender, advanced age, a history of smoking, obesity, hypertension, diabetes, malignancy, coronary heart disease, hypertension, COPD, CKD and chronic liver disease, were more likely to develop the severe form of the disease. The emergence of complications like shock, ARDS, AKI generally increased the risk of the disease developing into the severe condition.

Supporting information
S1 Checklist. PRISMA 2009 checklist.
(DOC)

S1 Fig. Funnel plot of (A) sex, (B) smoking history, (C) age, (D) BMI, (E) Chronic kidney disease, (F) Chronic obstructive pulmonary disease, (G) Coronary heart disease, (H) Malignancy, (I) Cerebrovascular disease, (J) Hypertension, (K) Diabetes, (L) Chronic liver disease, (M) Acute respiratory distress syndrome (ARDS), (N) Shock, (O) Acute kidney injury (AKI) and severe COVID-19 disease for the assessment of publication bias.
(TIF)

S1 Table. Search strategy in four electronic databases.
(DOCX)

Acknowledgments
We sincerely thank Associate Professor Yongzhen Yi for her professional opinion on statistical methods.

Author Contributions
Writing – original draft: Xinyang Li, Xianrui Zhong.
Writing – review & editing: Yongbo Wang, Xiantao Zeng, Ting Luo, Qing Liu.

References
1. World Health Organization. Coronavirus disease (COVID-19) outbreak, https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline#!/ (accessed 10 August 2020).
2. World Health Organization. Coronavirus disease (COVID-19) outbreak, https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports (accessed 9 March 2021).
3. Zhang J, Wu S, Xu L. Asymptomatic carriers of COVID-19 as a concern for disease prevention and control: more testing, more follow-up. Biosci Trends. 2020/04/24. 2020; 14: 206–208. https://doi.org/10.5582/bst.2020.03069 PMID: 32321904
4. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escaíera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020/03/18. 2020; 34: 101623. https://doi.org/10.1016/j.tmaid.2020.101623 PMID: 32179124
5. Lippi G, Henry BM. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir Med. 2020/05/19. 2020; 167: 105941. https://doi.org/10.1016/j.rmed.2020.105941 PMID: 32421537
6. Berlin I, Thomas D, Le Fauz AL, Cornuz J. COVID-19 and Smoking. Nicotine Tob Res. 2020/04/22. 2020; 22: 1650–1652. https://doi.org/10.1093/ntr/ntaa058 PMID: 3224236

7. Rodacki M. Severity of COVID-19 and diabetes mellitus: is there a lot to be learned. Arch Endocrinol Metab. 2020/06/20. 2020; 64: 195–196. https://doi.org/10.20945/2359-3997000000261 PMID: 32555983

8. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2009/01/01. 2009; 3: e123–30. PMID: 2163045

9. Ma LL, Wang YY, Yang ZH, Huang D, Weng H, Zeng XT. Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better? Mil Med Res. 2020/03/01. 2020; 7: 7. https://doi.org/10.1186/s40779-020-00238-3 PMID: 32112523

10. Miettinen OS. Proportion of disease caused or prevented by a given exposure, trait or intervention. American journal of epidemiology. 1974; 99(5):325–32. Epub 1974/05/01. https://doi.org/10.1093/oxfordjournals.aje.a121617 PMID: 4825599.

11. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020/02/08. 2020; 323: 1061–1069. https://doi.org/10.1001/jama.2020.1585 PMID: 32031570

12. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020/02/23. 2020; 75: 1730–1741. https://doi.org/10.1111/all.14238 PMID: 32077115

13. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020/02/29. 2020; 382: 1708–1720. https://doi.org/10.1056/NEJMoa2002032 PMID: 32109013

14. Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol. 2020/03/22. 2020; 92: 797–806. https://doi.org/10.1002/jmv.25783 PMID: 32198776

15. Hong KS, Lee KH, Chung JH, Shin KC, Choi EY, Jin HJ, et al. Clinical Features and Outcomes of 98 Patients Hospitalized with SARS-CoV-2 Infection in Daegu, South Korea: A Brief Descriptive Study. Yonsei Med J. 2020/05/12. 2020; 61: 431–437. https://doi.org/10.3349/ymj.2020.61.5.431 PMID: 32390367

16. Zhang YT, Deng AP, Hu T, Chen XG, Zhuang YL, Tan XH, et al. [Clinical outcomes of COVID-19 cases and influencing factors in Guangdong province]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020/04/29. 2020; 41: E057. https://doi.org/10.3760/cma.j.cn112338-20200318-00378 PMID: 32340095

17. Chen Q, Zheng Z, Zhang C, Zhang X, Wu H, Wang J, et al. Clinical characteristics of 145 patients with coronavirus disease 2019 (COVID-19) in Taizhou, Zhejiang, China. Infection. 2020/04/29. 2020; 48: 543–551. https://doi.org/10.1007/s15010-020-01432-5 PMID: 32342479

18. Zhao XY, Xu XX, Yin HS, Hu QM, Xiong T, Tang YY, et al. Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study. BMC Infect Dis. 2020/04/30. 2020; 20: 311. https://doi.org/10.1186/s12879-020-05010-w PMID: 32345226

19. Zhong Y, Xiong C, Liu Y, Qian X, Tang Y, Liu L, et al. Epidemiological and clinical characteristics analysis of COVID-19 in the surrounding areas of Wuhan, Hubei Province in 2020. J Med Virol. 2020/05/04. 2020; 92: 104821. https://doi.org/10.1002/jmv.25783 PMID: 32360481

20. Hu L, Chen S, Fu Y, Gao Z, Long H, Wang JM, et al. Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Hospitalized Patients in Wuhan, China. Clin Infect Dis. 2020/05/04. 2020. https://doi.org/10.1093/cid/ciaa539 PMID: 32361738

21. Cai Q, Huang D, Ou P, Yu H, Zhu Z, Xia Z, et al. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. Allergy. 2020/04/03. 2020; 75: 1742–1752. https://doi.org/10.1121/all. 14309 PMID: 32239761

22. Wang Y, Liao B, Guo Y, Li F, Lei C, Zhang F, et al. Clinical Characteristics of Patients Infected With the Novel 2019 Coronavirus (SARS-CoV-2) in Guangzhou, China. Open Forum Infect Dis. 2020/06/25. 2020; 7: ofaa187. https://doi.org/10.1093/ofid/ofaa187 PMID: 32577426

23. Buckner FS, McCulloch DJ, Atluri V, Blain M, McGuffin SA, Nalla AK, et al. Clinical Features and Outcomes of 105 Hospitalized patients with COVID-19 in Seattle, Washington. Clin Infect Dis. 2020/05/24. 2020; 7: mtaa71. https://doi.org/10.1093/cid/mtaa71 PMID: 32444880

24. Yang Q, Xie L, Zhang W, Zhao L, Wu H, Jiang J, et al. Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019. J Clin Pharm Ther. 2020/05/26. 2020; 45: 609–616. https://doi.org/10.1111/jcpt.13170 PMID: 32449224

25. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. Am J Respir Crit Care Med. 2020/04/11. 2020; 201: 1380–1388. https://doi.org/10.1164/rccm.202002-0445OC PMID: 32275452
26. Suleyman G, Fadel RA, Malette KM, Hammond C, Abdulla H, Entz A, et al. Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit. JAMA Netw Open. 2020;06/17. 2020; 3: e2012270. https://doi.org/10.1001/jamanetworkopen.2020.12270 PMID: 32543702

27. Cao Z, Li T, Liang L, Wang H, Wei F, Meng S, et al. Clinical characteristics of Coronavirus Disease 2019 patients in Beijing, China. PLoS One. 2020/06/20. 2020; 15: e0234764. https://doi.org/10.1371/journal.pone.0234764 PMID: 3255674

28. Shahriariad R, Khodamoradi Z, Erfani A, Hosseinpour H, Ranjbar K, Emami Y, et al. Epidemiological and clinical features of 2019 novel coronavirus diseases (COVID-19) in the South of Iran. BMC Infect Dis. 2020/06/20. 2020; 20: 427. https://doi.org/10.1186/s12879-020-05128-x PMID: 32552751

29. Nie Y, Li J, Huang X, Guo W, Zhang X, Ma Y, et al. Epidemiological and clinical characteristics of 671 COVID-19 patients in Henan Province, China. Int J Epidemiol. 2020/06/27. 2020. https://doi.org/10.1093/ije/dya081 PMID: 32588051

30. Zhang SY, Lian JS, Hu JH, Zhang XL, Lu YF, Cai H, et al. Clinical characteristics of different subtypes and risk factors for the severity of illness in patients with COVID-19 in Zhejiang, China. Infect Dis Poverty. 2020/07/10. 2020; 9: 85. https://doi.org/10.1186/s40249-020-00710-6 PMID: 32641121

31. Cai Q, Chen F, Wang T, Luo F, Liu X, Wu Q, et al. Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China. Diabetes Care. 2020/05/16. 2020; 43: 1392–1398. https://doi.org/10.2337/dc20-0576 PMID: 32409502

32. Gregoriano C, Koch D, Haubitz S, Conen A, Fux CA, Mueller B, et al. Characteristics, predictors and outcomes among 99 patients hospitalised with COVID-19 in a tertiary care centre in Switzerland: an observational analysis. Swiss Med Wkly. 2020/07/16. 2020; 150: w20316. https://doi.org/10.4414/smw.2020.2034607

33. Ghweil AA, Hassan MH, Khodeary A, Mohamed AO, Mohamed HM, Abdelaziz AA, et al. Characteristics, Outcomes and Indicators of Severity for COVID-19 Among Sample of ESNA Quarantine Hospital’s Patients, Egypt: A Retrospective Study. Infect Drug Resist. 2020/08/09. 2020; 13: 2375–2383. https://doi.org/10.2147/IDR.S263489 PMID: 32763012

34. Yu C, Lei Q, Li W, Wang X, Li W, Liu W. Epidemiological and clinical characteristics of 1663 hospitalized patients infected with COVID-19 in Wuhan, China: a single-center experience. J Infect Public Health. 2020/07/29. 2020; 13: 1202–1208. https://doi.org/10.1016/j.jiph.2020.07.002 PMID: 32718894

35. Wang B, Wang Z, Zhao J, Zeng X, Wu M, Wang S, et al. Epidemiological and clinical course of 483 patients with COVID-19 in Wuhan, China: a single-center, retrospective study from the mobile cabin hospital. Eur J Clin Microbiol Infect Dis. 2020/07/20. 2020; 1–7. https://doi.org/10.1007/s10096-020-03927-3 PMID: 32683596

36. Lee JY, Hong SW, Hyun M, Park JS, Lee JH, Suh YS, et al. Epidemiological and clinical characteristics of coronavirus disease 2019 in Daegu, South Korea. Int J Infect Dis. 2020/07/24. 2020; 98: 462–466. https://doi.org/10.1016/j.ijid.2020.07.017 PMID: 32702415

37. Xu X, Yu MQ, Shen Q, Wang LZ, Yan RD, Zhang MY, et al. Analysis of inflammatory parameters and disease severity for 88 hospitalized COVID-19 patients in Wuhan, China. Int J Med Sci. 2020/08/14. 2020; 17: 2052–2062. https://doi.org/10.7150/ijms.47935 PMID: 32788884

38. Wei Y, Zeng W, Huang X, Li J, Qiu X, Li H, et al. Clinical characteristics of 276 hospitalized patients with coronavirus disease 2019 in Zengdu District, Hubei Province: a single-center descriptive study. BMC Infect Dis. 2020/07/31. 2020; 20: 549. https://doi.org/10.1186/s12879-020-05252-8 PMID: 32727456

39. Liu S, Luo H, Wang Y, Cuevas LE, Wang D, Ju S, et al. Clinical characteristics and risk factors of patients with severe COVID-19 in Jiangsu province, China: a retrospective multicentre cohort study. BMC Infect Dis. 2020/08/09. 2020; 20: 584. https://doi.org/10.1186/s12879-020-05314-x PMID: 32762665

40. Wang Y, Zhou Y, Yang Z, Xia D, Hu Y, Geng S. Clinical Characteristics of Patients with Severe Pneumonia Caused by the SARS-CoV-2 in Wuhan, China. Respir Res. 2020/08/26. 2020; 1–9. https://doi.org/10.1186/s12931-020-01510-0 PMID: 32957997
44. Xiong S, Liu L, Lin F, Shi J, Han L, Liu H, et al. Clinical characteristics of 116 hospitalized patients with COVID-19 in Wuhan, China: a single-centered, retrospective, observational study. BMC infectious diseases. 2020; 20(1):787. Epub 2020/10/24. https://doi.org/10.1186/s12879-020-05452-2 PMID: 33092539; PubMed Central PMID: PMC7578439.

45. Lee SG, Park GU, Moon YR, Sung K. Clinical Characteristics and Risk Factors for Fatality and Severity in Patients with Coronavirus Disease in Korea: A Nationwide Population-Based Retrospective Study Using the Korean Health Insurance Review and Assessment Service (HIRA) Database. International journal of environmental research and public health. 2020; 17(22). Epub 2020/11/22. https://doi.org/10.3390/ijerph17228559 PMID: 33218161; PubMed Central PMID: PMC7689394.

46. Kim K, Choi JW, Moon J, Akilov H, Tuychiev L, Rakhimov B, et al. Clinical Features of COVID-19 in Uzbekistan. Journal of Korean medical science. 2020; 35(45):e404. Epub 2020/11/25. https://doi.org/10.3346/jkms.2020.35.e404 PMID: 33230989; PubMed Central PMID: PMC7683242.

47. Ren L, Yao D, Cui Z, Chen S, Yan H. Coronavirus Disease 2019 patients with different disease severity or age range: A single-center study of clinical features and prognosis. Medicine. 2020; 99(49):e22899. Epub 2020/12/09. https://doi.org/10.1080/0886022X.2019.1605294 PMID: 31057017; PubMed Central PMID: PMC7717834.

48. Vial MR, Peters A, Pérez I, Spencer-Sandino M, Barbé M, Porte L, et al. Covid-19 in South America: clinical and epidemiological characteristics among 381 patients during the early phase of the pandemic in Santiago, Chile. BMC infectious diseases. 2020; 20(1):955. Epub 2020/12/16. https://doi.org/10.1186/s12879-020-05665-5 PMID: 33317458; PubMed Central PMID: PMC7734456.

49. Lv Z, Lv S. Clinical characteristics and analysis of risk factors for disease progression of COVID-19: A retrospective Cohort Study. International journal of biological sciences. 2020; 17(1):1–7. Epub 2021/01/05. https://doi.org/10.3390/jibs.17010005 PMID: 33390828; PubMed Central PMID: PMC7757033.

50. Zhang N, Zhang H, Tang Y, Zhang H, Ma A, Xu F, et al. Risk factors for illness severity in patients with COVID-19 pneumonia: a prospective cohort study. International journal of medical sciences. 2021; 18(4):921–8. Epub 2021/01/19. https://doi.org/10.7150/jims.51205 PMID: 33456349; PubMed Central PMID: PMC7807193.

51. Zhang Q, Wang Z, Lv Y, Zhao J, Dang Q, Xu D, et al. Clinical features and prognostic factors of patients with COVID-19 in Henan Province, China. Human cell. 2021; 34(2):419–35. Epub 2021/02/16. https://doi.org/10.1007/s13577-021-00499-y PMID: 33586121; PubMed Central PMID: PMC7882230.

52. Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020/04/27. 2020; 81: e16–e25. https://doi.org/10.1016/j.jinf.2020.04.021 PMID: 32335169.

53. Rahman A, Sathi NJ. Risk Factors of the Severity of COVID-19: a Meta-Analysis. medRxiv. 2020. https://doi.org/10.1111/jcp.13916 PMID: 33372407.

54. Vardavas CI, Nikitara K. COVID-19 and Smoking: A Systematic Review of the Evidence. Tob Induc Dis. 2020/03/25. 2020; 18: 20. https://doi.org/10.1183/tid.119324 PMID: 32060052.

55. Li J, He X, Yuan Y, Zhang W, Li X, Zhang Y, et al. Clinical characteristics, outcomes, and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia. Am J Infect Control. 2020/06/17. 2020; 99: 47–56. https://doi.org/10.1016/j.ajic.2020.06.008 PMID: 32540370.

56. Lippi G, Wong J, Henry BM. Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis. Pol Arch Intern Med. 2020/04/02. 2020; 130: 304–309. https://doi.org/10.20452/pamw.15272 PMID: 32231171.

57. Liu H, Chen S, Liu M, Nie H, Lu H. Comorbid Chronic Diseases are Strongly Correlated with Disease Severity among COVID-19 Patients: A Systematic Review and Meta-Analysis. Aging Dis. 2020/06/04. 2020; 11: 668–678. https://doi.org/10.14336/AD.2020.0502 PMID: 32489771.

58. Zhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L, et al. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis. Int J Infect Dis. 2020/07/30. 2020; 99: 47–56. https://doi.org/10.1016/j.ijid.2020.07.029 PMID: 32721533.

59. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020/03/17. 2020; 94: 91–95. https://doi.org/10.1016/j.ijid.2020.03.017 PMID: 32173574.

60. Conti P, Younes A. Coronavirus COVID-19/SARS-CoV-2 affects women less than men: clinical response to viral infection. J Biol Regul Homeost Agents. 2020/04/08. 2020; 34: 339–343. https://doi.org/10.23812/Editorial-Conti-3 PMID: 32253888.

61. Sama IE, Ravera A, Sansbeta BT, van Goor H, Ter Maaten JM, Cleland JGF, et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. Eur Hear J. 2020/05/11. 2020; 41: 1810–1817. https://doi.org/10.1093/eurheartj/ehaa373 PMID: 32388565.
62. Cai H. Sex difference and smoking predisposition in patients with COVID-19. Lancet Respir Med. 2020/03/15. 2020; 8: e20. https://doi.org/10.1016/S2213-2600(20)30117-X PMID: 32171067

63. Silva A, Moreira JC, Martins SR. COVID-19 and smoking: a high-risk association. Cad Saude Publica. 2020/05/20. 2020; 36: e00072020. https://doi.org/10.1590/0102-311X00072020 PMID: 32428076

64. Brake SJ, Barnsley K, Lu W, McAllinden KD, Eapen MS, Sohal SS. Smoking Uregulates Angiotensin-Converting Enzyme-2 Receptor: A Potential Adhesion Site for Novel Coronavirus SARS-CoV-2 (Covid-19). J Clin Med. 2020/04/05. 2020;9. https://doi.org/10.3390/jcm9030841 PMID: 32244852

65. Desai R, Singh S, Parekh T, Sachdeva S, Sachdeva R, Kumar G. COVID-19 and diabetes mellitus: A need for prudence in elderly patients from a pooled analysis. Diabetes Metab Syndr. 2020/05/22. 2020; 14: 683–685. https://doi.org/10.1016/j.dsx.2020.05.021 PMID: 32438333

66. Desai R, Singh S, Parekh T, Sachdeva S, Kumar L, Sachdeva R, et al. COVID-19 and Shock: A Cautionary Tale for Elderly Patients From a Pooled Analysis. Ann Emerg Med. 2020/05/31. 2020; 75: 789–791. https://doi.org/10.1016/j.annemergmed.2020.04.014 PMID: 32471584

67. Sharma A, Garg A, Rout A, Lave CJ. Association of Obesity With More Critical Illness in COVID-19. Mayo Clin Proc. 2020/08/31. 2020; 95: 2040–2042. https://doi.org/10.1016/j.mayocp.2020.06.046 PMID: 32861346

68. Hussain A, Mahawar K, Xia Z, Yang W, El-Hasani S. Obesity and mortality of COVID-19. Meta-analysis. Obes Res Clin Pr. 2020/07/15. 2020; 14: 295–300. https://doi.org/10.1016/j.orcp.2020.07.002 PMID: 32660813

69. Russell R. Covid-19 and COPD: A Personal Reflection. Int J Chron Obes Pulmon Dis. 2020/05/20. 2020; 15: 883–884. https://doi.org/10.2147/COPD.S255101 PMID: 3245514

70. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. J Res Cardiol. 2020/03/13. 2020;109:531–538. https://doi.org/10.1007/s00392-020-01626-9 PMID: 32161990

71. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005/05/18. 2005; 111: 2605–2610. https://doi.org/10.1161/CIRCULATIONAHA.104.510461 PMID: 15897343

72. Klimas J, Olvedy M, Ochodnicky-Mackovicova K, Kruzliak P, Cacanyova S, Kristek F, et al. Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats. J Cell Mol Med. 2015/03/15. 2015; 19: 1965–1974. https://doi.org/10.1111/jcmm.12573 PMID: 25766467

73. Pranata R, Lim MA, Huang I, Raharjo SB, Lukito AA. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression. J Renin Angiotensin Aldosterone Syst. 2020/05/16. 2020; 21: 1470320320926899. https://doi.org/10.1177/1470320320926899 PMID: 32408793

74. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005/07/08. 2005; 436: 112–116. https://doi.org/10.1038/nature03712 PMID: 16001071

75. Pai R, Bhansali A. COVID-19, diabetes mellitus and ACE2: The conundrum. Diabetes Res Clin Pr. 2020/04/03. 2020; 162: 108132. https://doi.org/10.1016/j.diabres.2020.108132 PMID: 32234504

76. Giannakoulis VG, Papoutsis E, Siempos II. Effect of Cancer on Clinical Outcomes of Patients With COVID-19: A Meta-Analysis of Patient Data. JCO Glob Oncol. 2020/06/09. 2020; 6: 799–808. https://doi.org/10.1200/GO.20.00225 PMID: 32511066

77. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020/04/16. 2020; 146: 110–118. https://doi.org/10.1016/j.jaci.2020.04.006 PMID: 32294485

78. Imig JD, Ryan MJ. Immune and inflammatory role in renal disease. Compr Physiol. 2013/05/31. 2013; 3: 957–976. https://doi.org/10.1002/cphy.c120028 PMID: 23720336

79. Oyelade T, Alqahtani J, Canciani G. Prognosis of COVID-19 in Patients with Liver and Kidney Diseases: An Early Systematic Review and Meta-Analysis. Trop Med Infect Dis. 2020/05/21. 2020;5. https://doi.org/10.3390/tropicalmed6010005 PMID: 33383742

80. Kulkarni A V, Kumar P, Tevethia H V, Premkumar M, Arab JP, Candia R, et al. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. Aliment Pharmacol Ther. 2020/07/09. 2020; 52: 584–599. https://doi.org/10.1111/apt.15916 PMID: 32638436

81. Whyte CS, Morrow GB, Mitchell JL, Chowdary P, Mutch NJ. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. J Thromb Haemost. 2020/04/25. 2020; 18: 1548–1555. https://doi.org/10.1111/jth.14872 PMID: 32329246
82. Choudhury R, Barrett CD, Moore HB, Moore EE, McIntyre RC, Moore PK, et al. Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis. World J Emerg Surg. 2020/04/22. 2020; 15: 29. https://doi.org/10.1186/s13017-020-00305-4 PMID: 32312290

83. Wang J, Hajizadeh N, Moore EE, McIntyre RC, Moore PK, Veress LA, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series. J Thromb Haemost. 2020/04/09. 2020; 18: 1752–1755. https://doi.org/10.1111/jth.14828 PMID: 32267998

84. Gabarre P, Dumas G, Dupont T, Darmon M, Azoulay E, Zafrani L. Acute kidney injury in critically ill patients with COVID-19. Intensive Care Med. 2020/06/14. 2020; 46: 1339–1348. https://doi.org/10.1007/s00134-020-06153-9 PMID: 32533197

85. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes care. 2019; 42(Suppl 1):S13–s28. Epub 2018/12/19. https://doi.org/10.2337/dc19-S002 PMID: 30559228.